FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:296-301 February 1, 1996 Number 5 Next

	Full Text PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival.

Methods We conducted a 12-week prospective, randomized, multicenter open trial comparing the effects of the continuous intravenous infusion of epoprostenol (formerly called prostacyclin) plus conventional therapy with those of conventional therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Association functional class III or IV).

Results Exercise capacity was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362 m at 12 weeks vs. 315 m at base line), but it decreased in the 40 patients treated with conventional therapy alone (204 m at 12 weeks vs. 270 m at base line; P<0.002 for the comparison of the treatment groups). Indexes of the quality of life were improved only in the epoprostenol group (P<0.01).

Hemodynamics improved at 12 weeks in the epoprostenol-treated patients. The changes in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 percent and +3 percent, respectively (difference in mean change, -6.7 mm Hg; 95 percent confidence interval, -10.7 to -2.6 mm Hg; P<0.002), and the mean changes in pulmonary vascular resistance for the epoprostenol and control groups were -21 percent and +9 percent, respectively (difference in mean change, -4.9 mm Hg per liter per minute; 95 percent confidence interval, -7.6 to -2.3 mm Hg per liter per minute; P<0.001). Eight patients died during the study, all of whom had been randomly assigned to conventional therapy (P = 0.003). Serious complications included four episodes of catheter-related sepsis and one thrombotic event.

Conclusions As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.

Source Information

From the Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York (R.J.B.); the Department of Medicine, University of Maryland, Baltimore (L.J.R.); the Department of Pediatrics, University of North Carolina, Chapel Hill (W.A.L.); the Department of Medicine, Mayo Medical Center, Rochester, Minn. (M.D.M.); the Department of Medicine, University of Illinois at Chicago (S.R.); the Department of Medicine, University of Colorado Health Sciences Center, Denver (D.B.B., B.M.G.); the Department of Medicine, Duke University Medical Center, Durham, N.C. (V.F.T.); the Department of Medicine, University of Alabama, Birmingham (R.C.B.); the Department of Medicine, Harbor–UCLA Medical Center, Torrance, Calif. (B.H.B.); the Department of Medicine, Cedars–Sinai Medical Center, Los Angeles (S.K.K.); the Department of Medicine, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal (D.L.); the Department of Medicine, Baylor College of Medicine, Houston (C.A.K.); the Department of Medicine, Presbyterian–University Hospital, University of Pittsburgh, Pittsburgh (S.M., B.F.U.); and the Medical Division, Burroughs Wellcome, Research Triangle Park, N.C. (L.M.C., M.M.J., S.D.B., D.S., J.W.C.).

Address reprint requests to Dr. Barst at the Division of Pediatric Cardiology, Department of Pediatrics, BH 262N, Columbia University College of Physicians and Surgeons, 3959 Broadway, New York, NY 10032.

Full Text of this Article

Related Letters:

Intravenous Epoprostenol for Primary Pulmonary Hypertension
Schulze-Neick I., Lange P. E., Haas N. A., Higenbottam T., Barst R. J., Rubin L. J.
Extract | Full Text  
N Engl J Med 1996; 334:1477-1478, May 30, 1996. Correspondence

Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension
Botney M., Rich S., McLaughlin V. V.
Extract | Full Text  
N Engl J Med 1998; 338:1773-1774, Jun 11, 1998. Correspondence

This article has been cited by other articles:

• Handoko, M. L., Lamberts, R. R., Redout, E. M., de Man, F. S., Boer, C., Simonides, W. S., Paulus, W. J., Westerhof, N., Allaart, C. P., Vonk-Noordegraaf, A. (2009). Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am. J. Physiol. Heart Circ. Physiol. 297: H1752-H1759 [Abstract] [Full Text]  
• Authors/Task Force Members, , Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J. S., Gomez-Sanchez, M. A., Jondeau, G., Klepetko, W., Opitz, C., Peacock, A., Rubin, L., Zellweger, M., Simonneau, G., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., McGregor, K., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P., Widimsky, P., Document Reviewers, , Sechtem, U., Al Attar, N., Andreotti, F., Aschermann, M., Asteggiano, R., Benza, R., Berger, R., Bonnet, D., Delcroix, M., Howard, L., Kitsiou, A. N, Lang, I., Maggioni, A., Nielsen-Kudsk, J. E., Park, M., Perrone-Filardi, P., Price, S., Domenech, M. T. S., Vonk-Noordegraaf, A., Zamorano, J. L. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537 [Full Text]  
• BADESCH, D. B., McGOON, M. D., BARST, R. J., TAPSON, V. F., RUBIN, L. J., WIGLEY, F. M., KRAL, K. M., RAPHIOU, I. H., CRATER, G. D. (2009). Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol. The Journal of Rheumatology 36: 2244-2249 [Abstract] [Full Text]  
• Hekier, E., Mandel, J. (2009). A 22-Year-Old Woman With Unexplained Dyspnea. Chest 136: 867-876 [Full Text]  
• Troy, P. J., Waxman, A. B. (2009). Review: Portopulmonary hypertension: challenges in diagnosis and management. Therapeutic Advances in Gastroenterology 2: 281-286 [Abstract]  
• Sun, C.-K., Lee, F.-Y., Sheu, J.-J., Yuen, C.-M., Chua, S., Chung, S.-Y., Chai, H.-T., Chen, Y.-T., Kao, Y.-H., Chang, L.-T., Yip, H.-K. (2009). Early Combined Treatment with Cilostazol and Bone Marrow-Derived Endothelial Progenitor Cells Markedly Attenuates Pulmonary Arterial Hypertension in Rats. J. Pharmacol. Exp. Ther. 330: 718-726 [Abstract] [Full Text]  
• Rubenfire, M., Lippo, G., Bodini, B. D., Blasi, F., Allegra, L., Bossone, E. (2009). Evaluating Health-Related Quality of Life, Work Ability, and Disability in Pulmonary Arterial Hypertension: An Unmet Need. Chest 136: 597-603 [Abstract] [Full Text]  
• Provencher, S., Sitbon, O. (2009). Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence. Eur Respir J 34: 7-9 [Full Text]  
• Peacock, A. J., Naeije, R., Galie, N., Rubin, L. (2009). End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?. Eur Respir J 34: 231-242 [Abstract] [Full Text]  
• Hoeper, M. M., Gall, H., Seyfarth, H. J., Halank, M., Ghofrani, H. A., Winkler, J., Golpon, H., Olsson, K. M., Nickel, N., Opitz, C., Ewert, R. (2009). Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 34: 132-137 [Abstract] [Full Text]  
• Church, A C, Sanabria, D, Peacock, A, Johnson, M (2009). Epoprostenol use in a National Pulmonary Hypertension Centre from 1997 to 2007. Thorax 64: 642-642 [Full Text]  
• Badesch, D. B., Champion, H. C., Gomez Sanchez, M. A., Hoeper, M. M., Loyd, J. E., Manes, A., McGoon, M., Naeije, R., Olschewski, H., Oudiz, R. J., Torbicki, A. (2009). Diagnosis and assessment of pulmonary arterial hypertension.. J Am Coll Cardiol 54: S55-S66 [Abstract] [Full Text]  
• Barst, R. J., Gibbs, J. S. R., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Rubin, L. J., Sitbon, O., Tapson, V. F., Galie, N. (2009). Updated evidence-based treatment algorithm in pulmonary arterial hypertension.. J Am Coll Cardiol 54: S78-S84 [Abstract] [Full Text]  
• Galie, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R. J., on behalf of the Pulmonary Arterial Hypertension a, (2009). Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation 119: 2894-2903 [Abstract] [Full Text]  
• Jing, Z-C., Jiang, X., Han, Z-Y., Xu, X-Q., Wang, Y., Wu, Y., Lv, H., Ma, C-R., Yang, Y-J., Pu, J-L. (2009). Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 33: 1354-1360 [Abstract] [Full Text]  
• McLaughlin, V., Humbert, M., Coghlan, G., Nash, P., Steen, V. (2009). Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 48: iii25-iii31 [Abstract] [Full Text]  
• Faughnan, M. E., Granton, J. T., Young, L. H. (2009). The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J 33: 1186-1194 [Abstract] [Full Text]  
• McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., Rubin, L. J., Tapson, V. F., Varga, J. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53: 1573-1619 [Full Text]  
• Writing Committee Members, , McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., Rubin, L. J., Tapson, V. F., Varga, J. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119: 2250-2294 [Full Text]  
• Pesaturo, K. A., Johnson, P. N., Ramsey, E. Z. (2009). Pediatric Pulmonary Hypertension: A Pharmacotherapeutic Review. Journal of Pharmacy Practice 22: 166-178 [Abstract]  
• Rich, S. (2009). The Effects of Vasodilators in Pulmonary Hypertension: Pulmonary Vascular or Peripheral Vascular?. Circ Heart Fail 2: 145-150 [Full Text]  
• Souza, R., Jardim, C. (2009). Trends in pulmonary arterial hypertension. ERR 18: 7-12 [Full Text]  
• Olschewski, H. (2009). Inhaled iloprost for the treatment of pulmonary hypertension. ERR 18: 29-34 [Abstract] [Full Text]  
• Galie, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M. L., Branzi, A. (2009). A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30: 394-403 [Abstract] [Full Text]  
• GARIN, M. C., HIGHLAND, K. B., SILVER, R. M., STRANGE, C. (2009). Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma. The Journal of Rheumatology 36: 330-336 [Abstract] [Full Text]  
• McGoon, M. D., Kane, G. C. (2009). Pulmonary Hypertension: Diagnosis and Management. Mayo Clin Proc. 84: 191-207 [Abstract] [Full Text]  
• Montani, D., Price, L. C., Dorfmuller, P., Achouh, L., Jais, X., Yaici, A., Sitbon, O., Musset, D., Simonneau, G., Humbert, M. (2009). Pulmonary veno-occlusive disease. Eur Respir J 33: 189-200 [Abstract] [Full Text]  
• Chin, K. M., Channick, R. N., de Lemos, J. A., Kim, N. H., Torres, F., Rubin, L. J. (2009). Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension. Chest 135: 130-136 [Abstract] [Full Text]  
• Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., Dearani, J. A., del Nido, P., Fasules, J. W., Graham, T. P. Jr, Hijazi, Z. M., Hunt, S. A., King, M. E., Landzberg, M. J., Miner, P. D., Radford, M. J., Walsh, E. P., Webb, G. D. (2008). ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e143-e263 [Full Text]  
• Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., Dearani, J. A., del Nido, P., Fasules, J. W., Graham, T. P. Jr, Hijazi, Z. M., Hunt, S. A., King, M. E., Landzberg, M. J., Miner, P. D., Radford, M. J., Walsh, E. P., Webb, G. D. (2008). ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: 1890-1947 [Full Text]  
• Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., Dearani, J. A., del Nido, P., Fasules, J. W., Graham, T. P. Jr, Hijazi, Z. M., Hunt, S. A., King, M. E., Landzberg, M. J., Miner, P. D., Radford, M. J., Walsh, E. P., Webb, G. D. (2008). ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: e714-e833 [Full Text]  
• Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., Dearani, J. A., del Nido, P., Fasules, J. W., Graham, T. P. Jr, Hijazi, Z. M., Hunt, S. A., King, M. E., Landzberg, M. J., Miner, P. D., Radford, M. J., Walsh, E. P., Webb, G. D. (2008). ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: 2395-2451 [Full Text]  
• Henkens, I. R., Gan, C. T.-J., van Wolferen, S. A., Hew, M., Boonstra, A., Twisk, J. W. R., Kamp, O., van der Wall, E. E., Schalij, M. J., Vonk Noordegraaf, A., Vliegen, H. W. (2008). ECG Monitoring of Treatment Response in Pulmonary Arterial Hypertension Patients. Chest 134: 1250-1257 [Abstract] [Full Text]  
• Simonneau, G., Rubin, L. J., Galie, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., Cossons, N., Sitbon, O., Badesch, D. B., for the PACES Study Group, (2008). Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial. ANN INTERN MED 149: 521-530 [Abstract] [Full Text]  
• Taichman, D. B. (2008). Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?. ANN INTERN MED 149: 583-585 [Full Text]  
• Baliga, R. S., Zhao, L., Madhani, M., Lopez-Torondel, B., Visintin, C., Selwood, D., Wilkins, M. R., MacAllister, R. J., Hobbs, A. J. (2008). Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 178: 861-869 [Abstract] [Full Text]  
• Peinado, V. I., Pizarro, S., Barbera, J. A. (2008). Pulmonary Vascular Involvement in COPD. Chest 134: 808-814 [Abstract] [Full Text]  
• Kuwano, K., Hashino, A., Noda, K., Kosugi, K., Kuwabara, K. (2008). A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery. J. Pharmacol. Exp. Ther. 326: 691-699 [Abstract] [Full Text]  
• Wells, A U, Hirani, N, on behalf of the BTS Interstitial Lung Disease Gui, (2008). Interstitial lung disease guideline. Thorax 63: v1-v58 [Full Text]  
• Denton, C P, Pope, J E, Peter, H-H, Gabrielli, A, Boonstra, A, van den Hoogen, F H J, Riemekasten, G, De Vita, S, Morganti, A, Dolberg, M, Berkani, O, Guillevin, L, (on behalf of the TRacleer Use in PAH associated w, (2008). Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 67: 1222-1228 [Abstract] [Full Text]  
• Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M. (2008). Review: Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2: 249-265 [Abstract]  
• Frey, R., Muck, W., Unger, S., Artmeier-Brandt, U., Weimann, G., Wensing, G. (2008). Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers. J Clin Pharmacol 48: 926-934 [Abstract] [Full Text]  
• Hill, N. S., Preston, I. R., Roberts, K. E. (2008). Patients with Pulmonary Arterial Hypertension in Clinical Trials: Who Are They?. Proc Am Thorac Soc 5: 603-609 [Abstract] [Full Text]  
• Gomberg-Maitland, M. (2008). Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials. Proc Am Thorac Soc 5: 610-616 [Abstract] [Full Text]  
• Ventetuolo, C. E., Benza, R. L., Peacock, A. J., Zamanian, R. T., Badesch, D. B., Kawut, S. M. (2008). Surrogate and Combined End Points in Pulmonary Arterial Hypertension. Proc Am Thorac Soc 5: 617-622 [Abstract] [Full Text]  
• Chen, H., Taichman, D. B., Doyle, R. L. (2008). Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension. Proc Am Thorac Soc 5: 623-630 [Abstract] [Full Text]  
• Lai, Y.-J., Pullamsetti, S. S., Dony, E., Weissmann, N., Butrous, G., Banat, G.-A., Ghofrani, H. A., Seeger, W., Grimminger, F., Schermuly, R. T. (2008). Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. 178: 188-196 [Abstract] [Full Text]  
• Lankhaar, J.-W., Westerhof, N., Faes, T. J.C., Tji-Joong Gan, C., Marques, K. M., Boonstra, A., van den Berg, F. G., Postmus, P. E., Vonk-Noordegraaf, A. (2008). Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J 29: 1688-1695 [Abstract] [Full Text]  
• Farber, H. W. (2008). The Status of Pulmonary Arterial Hypertension in 2008. Circulation 117: 2966-2968 [Full Text]  
• Galie, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Gerber, M. J., Dufton, C., Wiens, B. L., Rubin, L. J., for the Ambrisentan in Pulmonary Arterial Hyperten, (2008). Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117: 3010-3019 [Abstract] [Full Text]  
• Chin, K. M., Rubin, L. J. (2008). Pulmonary arterial hypertension.. J Am Coll Cardiol 51: 1527-1538 [Abstract] [Full Text]  
• Gomberg-Maitland, M., Olschewski, H. (2008). Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31: 891-901 [Abstract] [Full Text]  
• El-Haroun, H., Clarke, D. L., Deacon, K., Bradbury, D., Clayton, A., Sutcliffe, A., Knox, A. J. (2008). IL-1{beta}, BK, and TGF-{beta}1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L553-L562 [Abstract] [Full Text]  
• National Pulmonary Hypertension Centres of the UK, (2008). Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 94: i1-i41 [Full Text]  
• National Pulmonary Hypertension Centres of the UK, (2008). Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 63: ii1-ii41 [Full Text]  
• Otterdal, K., Andreassen, A. K., Yndestad, A., Oie, E., Sandberg, W. J., Dahl, C. P., Pedersen, T. M., Ueland, T., Gullestad, L., Brosstad, F. R., Aukrust, P., Damas, J. K. (2008). Raised LIGHT Levels in Pulmonary Arterial Hypertension: Potential Role in Thrombus Formation. Am. J. Respir. Crit. Care Med. 177: 202-207 [Abstract] [Full Text]  
• Pepke-Zaba, J., Gilbert, C., Collings, L., Brown, M. C. J. (2008). Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension. Chest 133: 183-189 [Abstract] [Full Text]  
• McSwain, C. S., Benza, R., Shapiro, S., Hill, N., Schilz, R., Elliott, C. G., Zwicke, D. L., Oudiz, R. J., Staszewski, J. P., Arneson, C. P., Wade, M., Zaccardelli, D., McLaughlin, V. (2008). Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion. J Clin Pharmacol 48: 19-25 [Abstract] [Full Text]  
• Wryobeck, J. M., Lippo, G., McLaughlin, V., Riba, M., Rubenfire, M. (2007). Psychosocial Aspects of Pulmonary Hypertension: A Review. Psychosomatics 48: 467-475 [Abstract] [Full Text]  
• Thenappan, T., Shah, S. J., Rich, S., Gomberg-Maitland, M. (2007). A USA-based registry for pulmonary arterial hypertension: 1982 2006. Eur Respir J 30: 1103-1110 [Abstract] [Full Text]  
• Naeije, R., Huez, S. (2007). Right ventricular function in pulmonary hypertension: physiological concepts. Eur Heart J Suppl 9: H5-H9 [Abstract] [Full Text]  
• Lang, I. M. (2007). Management of acute and chronic RV dysfunction. Eur Heart J Suppl 9: H61-H67 [Abstract] [Full Text]  
• Rubenfire, M., McLaughlin, V. V., Allen, R. P., Elliott, G., Park, M. H., Wade, M., Schilz, R. (2007). Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension: A Controlled Trial. Chest 132: 757-763 [Abstract] [Full Text]  
• Helman, D. L. Jr, Brown, A. W., Jackson, J. L., Shorr, A. F. (2007). Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials. Chest 132: 764-772 [Abstract] [Full Text]  
• Kuwano, K., Hashino, A., Asaki, T., Hamamoto, T., Yamada, T., Okubo, K., Kuwabara, K. (2007). 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. 322: 1181-1188 [Abstract] [Full Text]  
• Zhao, Q., Liu, Z., Wang, Z., Yang, C., Liu, J., Lu, J. (2007). Effect of Prepro-Calcitonin Gene-Related Peptide Expressing Endothelial Progenitor Cells on Pulmonary Hypertension. Ann. Thorac. Surg. 84: 544-552 [Abstract] [Full Text]  
• Tidswell, M., Higgins, T. L. (2007). The Anesthesiologist and Pulmonary Arterial Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 93-95  
• Edelman, J. D. (2007). Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 110-118 [Abstract]  
• Takaoka, S., Faul, J. L., Doyle, R. (2007). Current Therapies for Pulmonary Arterial Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 11: 137-148 [Abstract]  
• Badesch, D. B., Abman, S. H., Simonneau, G., Rubin, L. J., McLaughlin, V. V. (2007). Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 131: 1917-1928 [Abstract] [Full Text]  
• Lammers, A. E, Hislop, A. A, Flynn, Y., Haworth, S. G (2007). Epoprostenol treatment in children with severe pulmonary hypertension. Heart 93: 739-743 [Abstract] [Full Text]  
• Zhang, S., Patel, H. H., Murray, F., Remillard, C. V., Schach, C., Thistlethwaite, P. A., Insel, Paul. A., Yuan, J. X.-J. (2007). Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L1202-L1210 [Abstract] [Full Text]  
• Wang, X.-X., Zhang, F.-R., Shang, Y.-P., Zhu, J.-H., Xie, X.-D., Tao, Q.-M., Zhu, J.-H., Chen, J.-Z. (2007). Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension: A Pilot Randomized Controlled Trial. J Am Coll Cardiol 49: 1566-1571 [Abstract] [Full Text]  
• Widlitz, A. C., McDevitt, S., Ward, G. R., Krichman, A. (2007). Practical Aspects of Continuous Intravenous Treprostinil Therapy. Crit Care Nurse 27: 41-50 [Full Text]  
• Tapson, V. (2007). Atrial Septostomy: Why We Still Need It. Chest 131: 947-948 [Full Text]  
• Nana-Sinkam, S. P., Lee, J. D., Sotto-Santiago, S., Stearman, R. S., Keith, R. L., Choudhury, Q., Cool, C., Parr, J., Moore, M. D., Bull, T. M., Voelkel, N. F., Geraci, M. W. (2007). Prostacyclin Prevents Pulmonary Endothelial Cell Apoptosis Induced by Cigarette Smoke. Am. J. Respir. Crit. Care Med. 175: 676-685 [Abstract] [Full Text]  
• Mathai, S. C., Girgis, R. E., Fisher, M. R., Champion, H. C., Housten-Harris, T., Zaiman, A., Hassoun, P. M. (2007). Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 29: 469-475 [Abstract] [Full Text]  
• Montani, D., Souza, R., Binkert, C., Fischli, W., Simonneau, G., Clozel, M., Humbert, M. (2007). Endothelin-1/Endothelin-3 Ratio: A Potential Prognostic Factor of Pulmonary Arterial Hypertension. Chest 131: 101-108 [Abstract] [Full Text]  
• Provencher, S. (2006). Long-term treprostinil in pulmonary arterial hypertension: is the glass half full or half empty?. Eur Respir J 28: 1073-1075 [Full Text]  
• Barst, R. J., Galie, N., Naeije, R., Simonneau, G., Jeffs, R., Arneson, C., Rubin, L. J. (2006). Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28: 1195-1203 [Abstract] [Full Text]  
• Collins, N., Bastian, B., Quiqueree, L., Jones, C., Morgan, R., Reeves, G. (2006). Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). Eur J Echocardiogr 7: 439-446 [Abstract] [Full Text]  
• McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., Rubin, L. J. (2006). Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 174: 1257-1263 [Abstract] [Full Text]  
• Steiner, M. K., Preston, I. R., Klinger, J. R., Criner, G. J., Waxman, A. B., Farber, H. W., Hill, N. S. (2006). Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.. Chest 130: 1471-1480 [Abstract] [Full Text]  
• Fox, D J, Khattar, R S (2006). Pulmonary arterial hypertension: classification, diagnosis and contemporary management. Postgrad. Med. J. 82: 717-722 [Full Text]  
• Channick, R. N., Olschewski, H., Seeger, W., Staub, T., Voswinckel, R., Rubin, L. J. (2006). Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. J Am Coll Cardiol 48: 1433-1437 [Abstract] [Full Text]  
• Newman, J. H., Robbins, I. M. (2006). Exercise Training in Pulmonary Hypertension: Implications for the Evaluation of Drug Trials. Circulation 114: 1448-1449 [Full Text]